Intersect ENT Appoints Elisabeth Sandoval-Little to its Board

Intersect ENT Inc. has welcomed a new member to its executive board. The company recently appointed Elisabeth Sandoval-Little to replace Anthony Vernon, who resigned from the Board of Directors.

Vernon has served on the Intersect ENT Board since 2015 and is resigning to pursue other interests. 
 
“Tony has provided expert guidance to Intersect ENT and his impact fostering the growth of our company cannot be overstated,” said Thomas A. West, president and CEO at Intersect ENT. “On behalf of myself, the Board of Directors, and Intersect ENT’s management team, I would like to thank Tony for his dedicated and valued service to the company.”

Sandoval-Little currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Satsuma Pharmaceuticals Inc. and Vyne Therapeutics Inc. She is also on the board of privately-held Alastin Skincare. Sandoval-Little previously served as chief commercial officer and executive vice president of Corporate Strategy at Alder Biopharmaceuticals. She was chief commercial officer for Kythera Biopharmaceuticals and spent 23 years at Allergan in a variety of commercial leadership roles of increasing responsibility. Sandoval-Little began her career in research and development at Johnson & Johnson’s Ethicon division.

“We are pleased to welcome Elisabeth to the Intersect Board,” said West. “Elisabeth is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical and specialty therapeutics industries at both large market-leaders and development-stage companies. She has worked with products at all stages of the product lifecycle and her strong knowledge of the interplay between product and claims development and commercialization will be a great fit with Intersect ENT’s strategy and growth aspirations.”

Sandoval-Little earned an M.B.A. from Pepperdine University and a bachelor of science degree in biology from the University of California, Irvine.
  
“I am delighted to be joining Intersect ENT,” said Sandoval-Little. “With an established commercial presence, an expanding product base and a strong clinical program, this is an exciting time for the company. I look forward to contributing to its future growth.”